Cargando…

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

BACKGROUND: Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. METHODS: We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in So...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boeree, Martin J, Heinrich, Norbert, Aarnoutse, Rob, Diacon, Andreas H, Dawson, Rodney, Rehal, Sunita, Kibiki, Gibson S, Churchyard, Gavin, Sanne, Ian, Ntinginya, Nyanda E, Minja, Lilian T, Hunt, Robert D, Charalambous, Salome, Hanekom, Madeleine, Semvua, Hadija H, Mpagama, Stellah G, Manyama, Christina, Mtafya, Bariki, Reither, Klaus, Wallis, Robert S, Venter, Amour, Narunsky, Kim, Mekota, Anka, Henne, Sonja, Colbers, Angela, van Balen, Georgette Plemper, Gillespie, Stephen H, Phillips, Patrick P J, Hoelscher, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science ;, The Lancet Pub. Group 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159618/ https://www.ncbi.nlm.nih.gov/pubmed/28100438 http://dx.doi.org/10.1016/S1473-3099(16)30274-2

Ejemplares similares

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy
por: Ahmed, Mohamed I. M., et al.
Publicado: (2018)

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania
por: Mpagama, Stellah G., et al.
Publicado: (2023)

Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011)

Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania
por: Mbelele, Peter M., et al.
Publicado: (2021)

Systematic assessment of clinical and bacteriological markers for tuberculosis reveals discordance and inaccuracy of symptom-based diagnosis for treatment response monitoring
por: Mtafya, Bariki, et al.
Publicado: (2022)

Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome
por: Phillips, Patrick, et al.
Publicado: (2013)

Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients
por: Mtabho, Charles M, et al.
Publicado: (2019)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Performance of Tuberculosis Molecular Bacterial Load Assay Compared to Alere TB-LAM in Urine of Pulmonary Tuberculosis Patients with HIV Co-Infections
por: Mapamba, Daniel Adon, et al.
Publicado: (2023)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania
por: Juma, Saumu Pazia, et al.
Publicado: (2019)

Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania
por: Mpagama, Stellah G., et al.
Publicado: (2013)

Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study
por: Rachow, Andrea, et al.
Publicado: (2011)

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

“Honestly, this problem has affected me a lot”: a qualitative exploration of the lived experiences of people with chronic respiratory disease in Sudan and Tanzania
por: Egere, Uzochukwu, et al.
Publicado: (2023)

Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial
por: Sumari-de Boer, Marion, et al.
Publicado: (2019)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case study
por: Mpagama, Stellah G, et al.
Publicado: (2021)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania
por: Mpagama, Stellah G, et al.
Publicado: (2013)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Diagnostic Opportunities for Optimizing Management of Multidrug-Resistant Tuberculosis (MDR-TB) in Tanzania
por: Mpagama, Stellah G
Publicado: (2018)

Why being an expert – despite xpert –remains crucial for children in high TB burden settings
por: Bacha, Jason M., et al.
Publicado: (2017)

Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation
por: Mpagama, Stellah G., et al.
Publicado: (2019)

Where can Tanzania health system integrate clinical management of patients with dual tuberculosis and diabetes mellitus? A cross-sectional survey at varying levels of health facilities
por: Chamba, Nyasatu G., et al.
Publicado: (2022)

Experiences and perceptions of participants on the pathway towards clinical management of dual tuberculosis and diabetes mellitus in Tanzania
por: Chamba, Nyasatu G., et al.
Publicado: (2022)

Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis
por: Sariko, Margaretha, et al.
Publicado: (2017)

Gridlock from diagnosis to treatment of multidrug resistant tuberculosis (MDR-TB) in Tanzania: patients’ perspectives from a focus group discussion
por: Mpagama, Stellah G., et al.
Publicado: (2020)

Improvement in Plasma Drug Activity during the Early Treatment Interval among Tanzanian Patients with Multidrug-Resistant Tuberculosis
por: Ndusilo, Norah D., et al.
Publicado: (2015)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

Implementation of the ‘Removed Injectable modified Short-course regimens for EXpert Multidrug Resistant Tuberculosis’ (RISE study) in Tanzania: a protocol for a mixed-methods process evaluation
por: Kalolo, Albino, et al.
Publicado: (2022)

Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay
por: Sabiiti, Wilber, et al.
Publicado: (2020)

In Vivo Efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and In Vitro Activity of SQ109 Metabolites
por: Baek, Kyung-Hwa, et al.
Publicado: (2022)

Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania
por: Byashalira, Kenneth Cleophace, et al.
Publicado: (2022)

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
por: Dierig, A, et al.
Publicado: (2023)

Comparison of Overnight Pooled and Standard Sputum Collection Method for Patients with Suspected Pulmonary Tuberculosis in Northern Tanzania
por: Mpagama, Stellah G., et al.
Publicado: (2012)

What are the barriers to the diagnosis and management of chronic respiratory disease in sub-Saharan Africa? A qualitative study with healthcare workers, national and regional policy stakeholders in five countries
por: Mulupi, Stephen, et al.
Publicado: (2022)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5qsh92amen20s0c1541ql3km76